GlassScriptPhysician profile
Charlotte Dewitt
NPI 1104106509
$7,581.52
in general payments reported to CMS, 2019-2025
43 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,097 · 2022: $1,568 · 2023: $1,857 · 2024: $1,228 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,915.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,442.66 | 2021-2025 | |
| Amgen INC. | $766.76 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $737.60 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $614.48 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $481.43 | 2021-2025 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $387.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $354.13 | 2021-2025 | Rexulti |
| Eisai INC. | $314.72 | 2021-2025 | |
| Mylan Specialty L.P. | $221.46 | 2021-2024 | Yupelri |
| Pfizer INC. | $210.07 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.30 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $131.21 | 2021-2025 | Belsomra, Steglatro, Verquvo |
| Janssen Pharmaceuticals, INC | $130.55 | 2023-2024 | Spravato |
| Sumitomo Pharma America, INC. | $117.84 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $109.98 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlotte Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.